Excessive Immune Reactions Caused by Ipilimumab
Ipilimumab, also known as Y-drug or anti-CTLA4 monoclonal antibody, is a recombinant humanized monoclonal antibody developed by Bristol-Myers Squibb that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Since March 25, 2011, when the US FDA approved Yervoy (3 mg/kg) monotherapy for unresectable or metastatic melanoma, more…
Continue reading...